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368Endovascular repair of ruptured infrarenal
abdominal aortic aneurysm is associated with lower
30-day mortality and better 5-year survival rates
than open surgical repair
Manish Mehta, MD, MPH, John Byrne, MCh, FRCSI(Gen), R. Clement Darling III, MD,
Philip S. K. Paty, MD, Sean P. Roddy, MD, Paul B. Kreienberg, MD, John B. Taggert, MD,
and Paul Feustel, PhD, Albany, NY
Objective: Endovascular aneurysm repair (EVAR) decreases 30-day mortality for patients with ruptured abdominal aortic
aneurysms (r-AAAs) compared with open surgical repair (OSR). However, which patients beneﬁt or whether there is any
long-term survival advantage is uncertain.
Methods: From 2002 to 2011, 283 patients with r-AAA underwent EVAR (n[ 120 [42.4%]) or OSR (n[ 163 [57.6%]) at
AlbanyMedicalCenter.Alldatawere collectedprospectively.Patientswereanalyzedonan intention-to-treatbasis, andoutcomes
were evaluated by a logistic regression multivariable model. Kaplan-Meier analysis was used to compare long-term survival.
Results: The EVAR patients had a signiﬁcantly lower 30-day mortality than did the OSR patients (29/120 [24.2%] vs
72/163 [44.2%]; P < .005) and better cumulative 5-year survival (37% vs 26%; P < .005). Men beneﬁted more from
EVAR (mortality: 20.9% for EVAR vs 44.3% for OSR; P < .001) than did women (mortality: 32.4% vs 43.9%; P[ .39).
Age $80 years was a signiﬁcant predictor of death for EVAR (odds ratio [OR], 1.07; P [ .003) but not for OSR (OR,
1.04; P[ .056). Preexisting hypertension was a signiﬁcant predictor of survival for both EVAR (OR, 0.17; P < .001) and
OSR (OR, 0.48; P [ .021). Almost one fourth of EVAR patients (21/91 [23.1%]) required secondary interventions.
Survival advantage was maintained for EVAR patients to 5 years.
Conclusions: For r-AAA, EVAR reduces the 30-day mortality and improves long-term survival up to 5 years. However,
whereas open survivors require few graft-related interventions, up to 23% of EVAR patients will require reintervention
for endoleaks or graft migration. Close follow-up of all EVAR survivors is mandatory. (J Vasc Surg 2013;57:368-75.)Endovascular management of ruptured abdominal aortic
aneurysms (r-AAAs) is gaining acceptance.1,2 However,
which r-AAA patients beneﬁt most from endovascular aneu-
rysm repair (EVAR) or whether there is a cohort of patients
for whom open surgical repair (OSR) is still an acceptable
approach is unclear. Furthermore, long-term survival with
EVAR has not been reported.
Our aim was to determine if EVAR resulted in lower
30-day mortality than open repair and if certain groups
of patients have lower survival rates after EVAR than
others. We also wished to determine if there was any
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From January 5, 2002 to July 4, 2011, 283 patients
underwent surgery for ruptured infrarenal AAAs. Although
data on all patients were entered prospectively into a data-
base, this was a retrospective analysis. Outcomes were
30-day mortality, postoperative complications, and need
for secondary reinterventions. Late mortality data were
obtained from hospital records, primary care physicians,
local death notices, and the Social Security Death Index.
All EVARs were performed using United States Food
and Drug Administration-approved and commercially
available stent grafts. Our algorithm for management of
r-AAAs by EVAR has been detailed previously.3 Patient
selection for EVAR or OSR was dependent on the
surgeon’s discretion and experience. During EVAR, stent
grafts were chosen on the basis of availability and the
patient’s aortoiliac morphology. Early in our experience,
from 2002 to 2006, a single vascular surgeon performed
the vast majority of r-EVARs, and the majority of the
patients had aortoiliac morphology suitable for EVAR
with available stent grafts. With experience, particularly
over the past 5 years, most vascular surgeons in our group
have the ability and are comfortable with r-EVAR, result-
ing in less bias toward OSR in hemodynamically stable as
well as hemodynamically unstable patients and improve-
ments in our ability to treat patients with increasing
Table I. Demographic proﬁle of patients who
underwent surgery for ruptured abdominal aortic
aneurysm (r-AAA)
Variable Male Female Total
EVAR group
No. 86 (71.7%) 34 (28.3%) 120 (100%)
Age, mean (SD),
years
73.0 (10.7) 77.3 (9.2) 74.2 (10.4)
AAA diameter,
mean (SD), cm
6.5 (2.1) 6.3 (1.3) 6.4 (1.9)
OSR group
No. 107 (65.6%) 56 (34.4%) 163 (100%)
Age, mean (SD),
years
71.8 (8.5) 7.9 (8.2) 73.2 (8.6)
AAA diameter, mean
(SD), cm
7.5 (2.1) 7.8 (1.6) 7.6 (1.9)
Risk factor EVAR OSR
Diabetes mellitus 12% 12%
Hypertension 82% 56%
Coronary artery
disease
63% 34%
Active smoker 19% 22%
Ex-smoker 6% 4%
Chronic obstructive
pulmonary disease
17% 12%
Hyperlipidemia 43% 31%
Chronic renal failure 8% 5%
AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair;
OSR, open surgical repair; SD, standard deviation.
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accepted the “real-world scenario” clinical bias that
vascular surgeons face when evaluating r-AAA patients
for endovascular vs OSR. Juxtarenal and type IV thora-
coabdominal aortic aneurysms were excluded from this
analysis. Patients were analyzed on an intention-to-treat
basis. The patients were enrolled in r-EVAR vs r-OSR
based on the decision made in the emergency room,
and all patients who were allocated to the r-EVAR
group remained part of that group even if conversion
to open surgery was required. Postoperative follow-up
included clinical examination, duplex ultrasound imaging,
and computed tomographic angiography at 1, 6, and
12 months, and yearly thereafter for EVAR patients. The
OSR patients were seen yearly with graft ultrasound scan-
ning and computed tomographic angiography at 5 years.
Statistical analysis. Relationships between dichoto-
mous outcome variables (eg, presence of endoleaks,
complications, mortality) were analyzed using 22 tables
(Yates corrected c2 or Fisher exact test when expected
count in any cell was <5). For continuous variables, groups
were compared using a t-test, with P < .05 considered
statistically signiﬁcant. The effect of potential predictors
on 30-day mortality was assessed by logistic regression
with each variable ﬁrst considered separately. The effect of
all factors considered together was assessed by multiple
logistic regression with all main effects as candidates.
Stepwise regression was used to narrow the number of
factors to only those with statistically signiﬁcant effects
when considered in the presence of other factors. Kaplan-
Meier estimates, using the log-rank test, were used to
compare the primary outcome between groups for freedom
from death (survival).
RESULTS
Patient demographics are listed in Table I. From
January 5, 2002 to July 4, 2011, 283 patients underwent
EVAR (n ¼ 120 [42.4%]) or OSR (n ¼ 163 [57.6%])
for ruptured infrarenal AAAs. The majority were male
(EVAR: 86 men and 34 women; OSR: 107 men and
56 women). In the EVAR cohort, women were signiﬁ-
cantly older than men (mean [standard deviation (SD)]
77.3 [9.16] years vs 73.0 [10.67] years; P < .05). In the
OSR cohort, women were also signiﬁcantly older than
men (76.0 [8.2] years vs 71.8 [8.56] years; P < .005).
Intraoperative events. Mean estimated blood loss
(EBL) for EVAR patients was signiﬁcantly lower than for
OSR patients (357 [400] mL vs 2816 [2338] mL;
P < .005). The Gore Excluder endoprosthesis (W. L.
Gore & Associates, Flagstaff, Ariz) alone was used in 77
(64.2%) patients. In another 22 patients (18.3%) it was
used in combination with another device, and in one patient
(0.8%) it was used with two devices. Other stent grafts used
were Aneurx (Medtronic, Santa Rosa, Calif) (n¼ 9 [7.5%]),
Zenith (Cook Inc, Bloomington, Ind) (n ¼ 8 [6.7%]),
Talent (Medtronic) (n ¼ 2 [1.7%]), and Endurant (Med-
tronic) (n ¼ 1 [0.8%]). Overall, 26 r-EVAR patients
(21.7%) required aortic occlusion balloon during theprocedure. Four patients (3.3%) required conversion to
open surgery during their initial procedure. Of these four
patients, three died. There were 18 intraoperative deaths
(6.3%) among the 283 patients brought to the operating
room for repair of ruptured aneurysms. Twelve of 163
patients (7.4%) in the OSR group died on the table. Of
these 12 patients, 11 died before a device could be
implanted. In the EVAR group, there were six intraopera-
tive deaths (5%). All had a device implanted. The number
of intraoperative deaths was not signiﬁcantly different
between the two groups (P ¼ .42, c2 test).
Thirty-day mortality. The 30-day mortality for
EVAR patients was signiﬁcantly lower than for OSR
patients (EVAR: 29/120 [24.2%] vs OSR: 72/163
[44.2%]; P < .005; Table II). When analyzed by gender,
women undergoing EVAR had a higher mortality rate than
did men, although this difference was not statistically
signiﬁcant (11/34 [32.4%] vs 18/86 [20.9%]; P ¼ .27). In
the OSR group, women and men had similar a mortality
rate (25/57 [43.8%] vs 47/106 [44.3%]; P ¼ 1.0).
However, further analysis indicated that although men did
signiﬁcantly better after EVAR than OSR (mortality: 20.9%
vs 44.3%; P ¼ .001), among women there was no statis-
tically signiﬁcant advantage (EVAR mortality: 32.4% vs
OSR mortality: 43.9%; P ¼ .39). Older patients (age $80
years) undergoing EVAR had a signiﬁcantly higher
mortality than did younger patients (16/38 [42.1%] vs
13/82 [15.9%]; P < .005). However, in the OSR group,
there was no signiﬁcant age-related 30-day mortality
Table II. Cause of death among 29 patients who died
within 30 days of endovascular aneurysm repair (EVAR)
for ruptured abdominal aortic aneurysm (r-AAA)
Cause of death EVAR OSR
Intraoperative myocardial infarction/on table 5 12
Bleeding/coagulopathy 7b 29
Multisystem organ failure 5 16
Abdominal compartment syndrome 9 1
Colon ischemia 2 5
Acute respiratory distress syndromea 1 6
Gastrointestinal hemorrhage 0 1
Pulmonary embolism 0 1
Acute hepatic failure 0 1
OSR, Open surgical repair.
aAcute respiratory distress syndrome and 72 who died after OSR.
bOne patient with EVAR died on the table from bleeding.
Table III. Results of logistic regression for all patients
undergoing surgery for ruptured abdominal aortic
aneurysm (r-AAA) with odds for 30-day mortality for
independent variables considered separately and in
a multiple variable model
Variable OR 95% CI P value
Procedure type
Endovascular 1.000 Reference
Open 2.48 1.48-4.18 .001
Age (per year) 1.05 1.02-1.07 .001
Estimated blood
loss (per liter)
1.16 1.02-1.32 .02
AAA size (per cm) 1.45 1.23-1.71 <.001
Gender
Male 1.000 Reference
Female 1.22 0.73-2.06 .44
Diabetes mellitus 0.53 0.23-1.23 .14
Hypertension 0.30 0.18-0.50 <.001
Coronary artery
disease
0.72 0.44-1.19 .20
Smoker 0.47 0.24-0.93 .03
Ex-smoker 0.31 0.07-1.43 .13
Chronic obstructive
pulmonary disease
0.69 0.33-1.46 .34
Hyperlipidemia 0.88 0.53-1.46 .61
Renal failure 0.67 0.23-1.93 .46
Results of multiple variable stepwise procedure eliminating variables
until only statistically signiﬁcant ORs remain
Open 2.34 1.16-4.70 .017
Age (per year) 1.06 1.02-1.10 .002
Hypertension 0.37 0.18-0.76 .01
AAA size (per cm) 1.33 1.12-1.59 .001
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; OR, odds ratio.
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years: 51/122 [41.8%]; P ¼ .36).
Graft-related complications among survivors. After
EVAR, during the initial hospitalization, three patients
required additional secondary interventions: one required
Palmaz stent placement for treatment of type I endoleak,
one required additional proximal stent graft extension for
type I endoleak, and one required embolization for type
II endoleak. Among survivors, secondary interventions
for graft-related complications were performed in 21 of
91 patients (23.1%). Most were translumbar coil emboli-
zation procedures for persistent type II endoleaks (n ¼ 12
[13.2%]). Three patients (3.3%) with type I endoleaks had
Palmaz stents placed at the aortic neck, one patient (1.1%)
with stent graft migration from the proximal aortic neck
required stent graft extension, and one patient (1.1%)
required conversion to OSR. Two patients (2.2%) needed
femoroefemoral crossover for limb thrombosis. Three
patients (3.3%) had major graft-related complications: two
had stent grafts infections and required explantation with
an axillobifemoral bypass, and one sustained a rupture at 28
months and died 2 months after open repair. There were
no graft-related complications among the OSR survivors.
Nonfatal complications. Among the 91 survivors of
EVAR for r-AAA, complications were acute compartment
syndrome (ACS: n ¼ 6 [6.6%]), colon ischemia (n ¼ 5
[5.5%]; three required colectomy), respiratory failure
requiring ventilation (n ¼ 5 [5.5%]), small bowel obstruc-
tion (n ¼ 1 [1.1%]), lower extremity thrombosis (n ¼ 1
[1.1%]), acute renal failure requiring dialysis (n ¼ 1
[1.1%]), multisystem organ failure (n ¼ 1 [1.1%]), pro-
longed ileus (n ¼ 1 [1.1%]), and pulmonary embolism
(n ¼ 1 [1.1%]). Among the 91 survivors after OSR, in
the OSR group, non-fatal complications were myocardial
infarction (n ¼ 7), acute cholecystitis (n ¼ 5), acute renal
failure (n ¼ 8), wound infection (n ¼ 7), colon ischemia
(n ¼ 15), acute respiratory failure (n ¼ 11), gastrointestinal
hemorrhage (n ¼ 1), multisystem organ failure (n ¼ 3),
acute hepatic failure (n ¼ 1), sepsis syndrome (n ¼ 1), and
ACS (n ¼ 3). Graft infections occurred in two survivors,necessitating an axillobifemoral bypass with excision of
graft in one and femoroefemoral crossover and partial
excision of a bifurcated graft in the other.
Univariate and multivariable logistic regression.
When analyzingEVARandOSRgroups together (Table III),
the odds of 30-day mortality in the OSR patients was
2.48 times the odds in the EVAR group (95% conﬁdence
interval [CI], 1.48-4.18; P ¼ .001). Other signiﬁcant
predictors of 30-daymortality included age (odds ratio [OR],
1.05 per year; 95% CI ¼ 1.02-1.07; P ¼ .001), EBL (OR,
1.16 per liter; 95% CI, 1.02-1.32; P ¼ .02), and maximum
aneurysm diameter at presentation (OR, 1.45 per cm; 95%
CI, 1.23-1.71; P < .001). Compared with male gender,
female gender (OR, 1.22; 95% CI, 0.73-2.06; P ¼ .44) was
not a signiﬁcant predictor of early mortality. The only other
risk factors that signiﬁcantly predicted survival on univariate
analysis were a documented history of hypertension (OR, 0.3;
95% CI, 0.18-0.50; P < .001) and smoking (OR, 0.47; 95%
CI, 0.24-0.93; P ¼ .03). When all variables were considered
together in a multiple variable logistic model, OSR, age,
aneurysm size, and hypertension were signiﬁcantly associated
with 30-day mortality. When including the effects of age,
aneurysm size, and hypertension, odds of 30-day mortality
increased by a factor of 2.34 (95% CI, 1.16-4.70) with OSR
relative to EVAR.
Table IV. Results of logistic regression for open surgical
repair (OSR) and endovascular aneurysm repair (EVAR)
considered separately with odds or 30-day mortality for
independent variables considered separately and in
a multiple variable model
Variable OR 95% CI P value
OSR
OR for mortality at 30 days with each variable considered separately
Age (per year) 1.04 1.00-1.08 .056
Estimated blood loss
(per liter)
1.63 1.24-2.15 <.001
AAA size (per cm) 1.10 0.94-1.29 .228
Gender
Male 1.000 Reference
Female 0.92 0.48-1.77 .807
Diabetic 0.58 0.21-1.64 .307
Hypertension 0.48 0.25-0.90 .021
Coronary artery disease 0.62 0.32-1.22 .165
Smoker 0.32 0.13-0.76 .010
Ex-smoker 0.24 0.03-2.07 .193
Chronic obstructive
pulmonary disease
0.76 0.28-2.08 .598
Hyperlipidemia 0.71 0.36-1.40 .317
Renal failure 1.25 0.30-5.18 .758
Results of stepwise procedure eliminating variables until only
statistically signiﬁcant ORs remain
AAA size (per cm) 1.79 1.31-2.46 <.001
Coronary artery disease 0.21 0.07-0.62 .005
EVAR
ORs for mortality at 30 days with each variable considered separately
Age (per year) 1.07 1.03-1.13 .003
Estimated blood loss
(per liter)
1.64 0.63-4.31 .313
AAA size (per cm) 1.20 0.96-1.50 .109
Gender
Male 1.000 Reference
Female 1.18 0.74-4.39 .191
Diabetic 0.44 0.09-2.10 .306
Hypertension 0.17 0.07-0.47 .001
Coronary artery disease 1.47 0.62-3.45 .381
Smoker 0.84 0.28-2.52 .762
Ex-smoker 0.51 0.06 .536
Chronic obstructive
pulmonary disease
0.75 0.23-2.45 .634
Hyperlipidemia 1.64 0.71-3.79 .251
Renal failure 0.33 0.04-2.68 .297
Results of stepwise procedure eliminating variables until only
statistically signiﬁcant ORs remain
Age (per year) 1.08 1.02-1.13 .004
Hypertension 0.07 0.02-0.27 .000
Hyperlipidemia 4.66 1.37-15.85 .014
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; OR, odds ratio.
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(Table IV), univariate analysis again conﬁrmedage as a signif-
icant predictor of mortality for EVAR (OR, 1.07 per year;
95% CI, 1.03-1.13; P ¼ .003) but not quite for OSR (OR,
1.04; 95% CI, 1.00-1.08; P ¼ .056). The EBL predicted
death for OSR (OR, 1.63, 95% CI; P < .001) but not
EVAR (OR, 1.64; 95% CI, 0.63-4.31; P ¼ .313). A historyof hypertension strongly predicted survival in both groups
(EVAR: OR, 0.17; 95% CI, 0.07-0.47; P ¼ .001; OSR:
OR, 0.48; 95% CI, 0.25-0.90; P ¼ .021) but smoking
was only protective in OSR patients (OR, 0.32; 95% CI,
0.13-0.76; P ¼ .01).
When considering multiple variables simultaneously,
the result of stepwise elimination of variables until only
statistically signiﬁcant predictors remain showed age to be
signiﬁcant for EVAR patients (OR, 1.08 per year; 95%
CI, 1.02-1.13; P ¼ .004), whereas hypertension was
protective (OR, 0.07; 95% CI, 0.02-0.27; P < .001) and
hypercholesterolemia was not (OR, 4.66; 95% CI,
1.37-15.85; P ¼ .014). For OSR, aneurysm size (OR,
1.79 per cm; 95% CI, 1.31-2.46; P < .001) and coronary
artery disease (CAD: OR, 0.21; 95% CI, 0.07-0.62;
P ¼ .005) were signiﬁcant.
Life-table analysis. Kaplan-Meier estimates of survival
showed that when including all mortality starting at the
time of surgery, the overall survival curves were signiﬁcantly
better in the EVAR group (P ¼ .002, log-rank test) and
remained signiﬁcant at 5 years (Fig 1).However, the survivals
were not different (P ¼ .44, log-rank test) when only those
who survived for at least 30 days were considered (Fig 2).
Trends in utilization of EVAR and open surgery for
ruptured infrarenal AAAs. On analysis of the trends in
utilization of EVAR and OSR, there was an increase in
use of endovascular repair from 13% in 2002 to 73% in
2012 (Fig 3).
DISCUSSION
Despite advances in anesthesia, critical care, and open
surgical techniques, OSR for r-AAAs continues to have
appalling mortality rates.4 Although successful emergent
EVAR was reported almost 20 years ago,5 it has only
recently gained acceptance as a valid treatment.6-11 If the
results of this and other studies are borne out, EVAR repre-
sents a major advance in management of r-AAAs and a para-
digm shift in the treatment of a challenging condition.
This study represents the largest single-center experi-
ence reported to date12-24 and the ﬁrst to analyze long-
term patient survival after endovascular or OSR for
r-AAAs. We demonstrated that patients undergoing
EVAR for r-AAAs not only have signiﬁcantly lowermortality
but also better long-term survival. The difference, however,
was only statistically signiﬁcant in men. In women, EVAR
brought no statistically signiﬁcant beneﬁt. Nonetheless, we
suggest that an 11% reduction in femalemortality is clinically
important despite the P value. In mitigation, women were
older at the time of presentation than were men, but their
risk factor proﬁle and aneurysm size were no different. In
an earlier communication on elective EVAR in women, we
showed an excess of mortality in females that was partly
explained by aortic neck and iliac neck rupture in women.25
These events did not occur in this EVAR group.
We noted that 31% (9/23) of the deaths in our study
were due to the effects of ACS. In a previously published
report from our center on ruptured EVAR, several factors
seemed to contribute.26 These included the use of an aortic
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Fig 1. Cumulative survivals for patients undergoing open surgical repair (OPEN) and endovascular aneurysm repair
(EVAR) for ruptured abdominal aortic aneurysm (r-AAA).
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units of packed red blood cells), and coagulopathy with
elevated activated partial thromboplastin time at comple-
tion of the case. In our experience, patients with ACS
have signiﬁcantly increased mortality compared with those
without ACS. Our protocol for endovascular treatment of
r-AAA has evolved as a result. We now avoid systemic hep-
arinization, correct any coagulopathy in the perioperative
period, and, regardless of bladder pressures, perform lapa-
rotomy in patients who have more than one risk factor
for ACS and have abdominal distention. We believe that
these measures may decrease ACS-related morbidity and
mortality. In this experience of 120 r-EVAR patients,
19 (15.8%) required laparotomy for ACS.
The Achilles heel of EVAR, of course, is that it is not
always a permanent ﬁx. On follow-up, we found that
23.1% of our patients required further intervention. This is
a higher rate than usually reported; 57.1% (12/21) of
secondary procedures were performed for persistent type II
endoleaks in nonshrinking AAA after EVAR. However,
our reintervention rate is similar after EVAR for nonruptured
aneurysms.27Noneof ourOSRpatients needed intervention
for graft-related complications. Only four patients (3.3%)underwent emergent conversion from EVAR to OSR at
the time of initial procedure. Over the past decade, our
management of r-AAAs has evolved toward an EVAR-ﬁrst
approach, helped by a standardized protocol.3,28
On univariate analysis, age $80 years predictably was
associated with increased mortality in EVAR patients but
not in OSR patients, probably due to their high overall
mortality rate of 44.3%. Contrary to general perceptions,
female gender was not associated with increased mortality.
A surprising and counterintuitive ﬁnding of this study was
that a diagnosis of hypertension strongly predicted survival
in both groups on univariate testing. There are two
possible explanations. The ﬁrst is that hypertension was
undiagnosed in a large number of nonsurvivors and may
indicate a lack of attention to health care issues in this
patient group. The second is that many patients under-
going treatment for hypertension were taking b-blockers.
The beneﬁcial effect of b-adrenergic blockade on survival
for patients undergoing peripheral arterial surgery has
already been established.29 For similar reasons, a preo-
perative diagnosis of CAD was seen to have a protective
effect in patients undergoing OSR. This again could be
due to either a large incidence of undiagnosed CAD in
Cumulative Proportion Surviving In those who survived 30d
 (Kaplan-Meier; log rank test, p=0.44)
Complete  Censored
 EVAR
 OPEN0 12 24 36 48 60 72 84 96
Time (months)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cu
m
ul
at
ive
 P
ro
po
rti
on
 S
ur
viv
in
g
Fig 2. Cumulative survival for 30-day survivors of endovascular aneurysm repair (EVAR) and open surgical repair
(OPEN).
Fig 3. Trends in management of ruptured abdominal aortic aneurysm (r-AAA) at Albany Medical Center from 2002 to
2012.Expressed as percentageof cases per year.EVAR,Endovascular aneurysmrepair;OSR,opensurgical repair; r, ruptured.
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CAD had already undergone a coronary artery procedure,
either stenting or bypass, which could have proven beneﬁ-
cial in the emergency setting.In this study, we showed that there was a very signiﬁ-
cant 30-day survival beneﬁt of EVAR in the setting of
rupture. This beneﬁt was maintained for the full 5 years
of follow-up, and there was no convergence of all-cause
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ported. On a second analysis of life expectancy, we demon-
strated that if only 30-day survivors were considered,
survival was not signiﬁcantly different.
The results of this study suggest that EVAR should be
the ﬁrst-line treatment of ruptured infrarenal AAAs. This
requires a comfort level with EVAR for rupture and
a protocol that allows seamless transfer of patients with
r-AAAs from the emergency room to the operating
room. This may be beyond the remit of smaller community
hospitals. Inevitably, this raises the question of whether
patients should be transferred to an “AAA treatment”
center. Our current practice is, if possible, to regionalize
care and transfer all patients with ruptured aneurysm
from the 13 hospitals we serve to Albany Medical Center
for EVAR. An a priori analysis of 232 r-AAA patients
who underwent treatment at Albany Medical Center
showed that 136 (59%) were transferred from an outside
facility and 96 (41%) were direct admissions. An ad hoc
analysis of 20 consecutive transfer patients indicated that
the mean time interval from initiation of patient transfer
to arrival to Albany Medical Center was 1.2 hours.
The ultimate test of EVAR for ruptured aneurysms
would be a proper multicenter randomized controlled
trial.30 However, the improvements in mortality as well
as long-term survival using EVAR prompts us to question
whether that opportunity has already been lost due to
issues of equipoise.
Although this study represents the largest single-
center experience reported to date, there were limita-
tions. It was a retrospective review and not a case control
or randomized controlled trial. This was not a compar-
ator trial. The decision on whether or not to perform
EVAR on these patients was operator dependent, so
there may have been a selection bias in the EVAR group
toward those with less challenging anatomy. Operator
choice was dependent on the on-call surgeon’s comfort
level with EVAR in an elective and emergency setting.
During the study period, the number of surgeons who
were comfortable with EVAR increased; therefore,
EVAR was more likely to be offered in 2010 than in
2003. In this study, we hope we have identiﬁed areas
in which EVAR can still be improved upon, such as
greater awareness of ACS and the role it may play in
a patient’s death.CONCLUSIONS
For r-AAAs, EVAR offers a signiﬁcant reduction in
early mortality as well as long-term survival advantage
compared with OSR. The difference is particularly marked
in men. Although this difference is likely of clinical impor-
tance among women, we found no statistically signiﬁcant
beneﬁt. Over one fourth of patients undergoing EVAR,
however, will need reintervention, mostly for type II endo-
leaks. This series provides, for ﬁrst time, evidence that
patients with r-AAAs who undergo EVAR have a survival
advantage that is sustained over the long term.AUTHOR CONTRIBUTIONS
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